Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study

Grant, Jon E.; Odlaug, Brian L.; Chamberlain, Samuel R.; Kim, Suck Won

doi:10.1007/s00213-011-2347-8

Cited by 47 publications

(45 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have found that synthetic cannabinoids can reduce anxiety (Fabre and McLendon, 1981;Grant et al, 2011;Schindler et al, 2008). Cannabinoid effects on anxietylike behavior in rodents have recently been described (Braida et al, 2007;Jiang et al, 2005;Patel and Hillard, 2006).…”

Section: Anxietymentioning

confidence: 99%

Adult Neurogenesis and Mental Illness

Schoenfeld

Cameron

2014

Neuropsychopharmacol

155

108

View full text Add to dashboard Cite

Several lines of evidence suggest that adult neurogenesis, the production of new neurons in adulthood, may play a role in psychiatric disorders, including depression, anxiety, and schizophrenia. Medications and other treatments for mental disorders often promote the proliferation of new neurons; the time course for maturation and integration of new neurons in circuitry parallels the delayed efficacy of psychiatric therapies; adverse and beneficial experiences similarly affect development of mental illness and neurogenesis; and ablation of new neurons in adulthood alters the behavioral impact of drugs in animal models. At present, the links between adult neurogenesis and depression seem stronger than those suggesting a relationship between new neurons and anxiety or schizophrenia. Yet, even in the case of depression there is currently no direct evidence for a causative role. This article reviews the data relating adult neurogenesis to mental illness and discusses where research needs to head in the future.

show abstract

Section: Anxietymentioning

confidence: 99%

Adult Neurogenesis and Mental Illness

Schoenfeld

Cameron

2014

Neuropsychopharmacol

155

108

View full text Add to dashboard Cite

show abstract

“…The latter interpretation is supported by the observation that anxiety-spectrum disturbances and traumas in early developmental stages are a strong predictor for later cannabis use disorders [124-127]; furthermore, several lines of evidence suggest that the anxiolytic effects of THC may partially account for the high prevalence of cannabis use in patients affected by PTSD [128-131] and OCD [132]. Accordingly, recent clinical studies have shown that THC elicits therapeutic effects in OCD [133] and trichotillomania, an impulse-control disorder characterized by compulsive hair-pulling [134]. Nevertheless, prospective analyses show that cannabis use and dependence increase the risk for development of panic disorder [135], suggesting that the effect of cannabis may vary with respect to the nosological entities within the spectrum of anxiety disorders.…”

Section: Effects Of Cannabis and Cannabinoid Agents On Anxietymentioning

confidence: 99%

Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives

Tambaro¹,

Bortolato²

2012

RPCN

View full text Add to dashboard Cite

Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and experimental animals. The heterogeneity of cannabis-induced psychological outcomes reflects a complex network of molecular interactions between the key neurobiological substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivatives anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, respectively termed CB1 and CB2. The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concentrations of THC and other alkaloids (such as cannabidiol) within the plant itself. The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and highlights the challenges that should be overcome to harness the therapeutic potential of some of these compounds, all the while limiting the side effects associated with cannabis consumption.

show abstract

“…This was a 12-week open-label treatment study involving 14 female participants with TTM [22]. MGH-HPS scores decreased from a mean of 16.5 ± 4.4 at baseline to 8.7 ± 5.5 at study endpoint (p = 0.001).…”

Section: Cannabinoid Agonistsmentioning

confidence: 99%